Pharm Exec2h
IMU-856 Shows Promise in Celiac Disease: Histologic Protection and Nutrient Absorption Key to Advancing Trials
Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.
Pharm Exec4h
FDA Approves Vertex Pharmaceuticals’ First-in-Class Non-Opioid Journavx for Moderate-to-Severe Acute Pain
Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.
Pharm Exec8h
Why Frontline Sales Have and Will Continue to be a Foundation for Long-term Career Success
A Harvard Business School Healthcare Alumni Association Q&A with Paul Ollinger, one of Facebook’s first 250 employees.
Pharm Exec11h
Exploring EDETEK's R&D Cloud Launch
Shakthi Kumar, EDETEK, Inc.'s Chief Strategy and Business Officer, explores the company's launch of R&D Cloud.
Pharm Exec11h
New Survey Shows Public Support for Vaccines Still Strong
The survey shows voters, regardless of party affiliation, still support vaccines and are concerned about the reduction in ...
Pharm Exec11h
Senior Senators Introduce Bill to Force DTC Drug Advertisements to Include List Price
Direct-to-consumer advertising can be a controversial topic in the pharma industry. While the US isn’t the only other country ...